Celldex Therapeutics Inc (CLDX) financials
Celldex Therapeutics revenue and earnings by year
Celldex Therapeutics's revenue was $1.54 million in the fiscal year to December 31, 2025, down 78.0% from the year before. Net income was -$259 million, -16748.0% of revenue. Since the fiscal year to December 31, 2016, revenue has shrunk 15.2% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 7 | 7 | 2 | 5 | 7 | 4 | 10 | 13 | 7 |
| Revenue growth | -78.0% | 2.0% | 192.0% | -49.3% | -37.3% | 107.6% | -62.5% | -25.2% | 87.8% | — |
| Operating income | -287 | -195 | -155 | -122 | -73 | -68 | -56 | -186 | -122 | -133 |
| Operating margin | -18599.8% | -2778.9% | -2245.3% | -5180.1% | -1562.0% | -910.9% | -1576.4% | -1950.7% | -960.0% | -1958.7% |
| Net income | -259 | -158 | -141 | -112 | -71 | -60 | -51 | -151 | -93 | -129 |
| Net margin | -16748.0% | -2248.8% | -2054.8% | -4765.6% | -1516.0% | -805.9% | -1424.0% | -1585.1% | -730.1% | -1894.0% |
| Diluted EPS | -$3.90 | -$2.45 | -$2.92 | -$2.40 | -$1.64 | -$2.17 | -$3.58 | -$15.30 | -$10.91 | -$18.84 |
| Free cash flow | -214 | -160 | -109 | -105 | -62 | -42 | -47 | -76 | -102 | -116 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open CLDX in Markets.
See also: CLDX returns
No forecast, no recommendation. This page describes Celldex Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.